FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
BTIG affirms Mylan (Nasdaq: MYL) with a Buy rating and $60 price target as the company moves to release a generic EpiPen.
Analyst Timothy Chiang commented today, While Mylan has dealt with much criticism from the media and politicians, we believe the measures the company has announced... More
Leerink Partners analyst Jason Gerberry weighed in on Mylan (NASDAQ: MYL) after the company announced the launch of a generic version of its EpiPen amid price scrutiny.
Gerberry estimates the launch of an EpiPen authorized generic (AG) will have a... More

